Kusić R, Bosković B, Vojvodić V, Jovanović D
Fundam Appl Toxicol. 1985 Dec;5(6 Pt 2):S89-97. doi: 10.1093/toxsci/5.6part2.89.
After intramuscular administration of graded doses of HI-6 (62.5, 125, 250, and 500 mg) to 22 healthy men, it has been established that therapeutic concentrations of the oxime in plasma, arbitrarily taken as 4 micrograms/ml, were achieved by doses of 250 and 500 mg in about 5 min, and maintained from 2 to 3 hr. The two lowest doses have not been satisfactory in this respect. Of the total doses injected, from 56.3 to 62% of HI-6 was excreted into urine unchanged during the first 6 hr. No side-effects were reported by the subjects, nor revealed by clinical or laboratory tests during the study. Exceptional tolerance of HI-6 in man found in this study, along with its high efficiency proven in experimental poisoning by sarin, VX, and soman, make it the most promising oxime aimed at the treatment of human poisoning by known chemical warfare nerve agents.
对22名健康男性肌肉注射不同剂量(62.5、125、250和500毫克)的HI-6后,已确定血浆中肟的治疗浓度(任意设定为4微克/毫升)在250毫克和500毫克剂量下约5分钟即可达到,并维持2至3小时。在这方面,两个最低剂量并不理想。在前6小时内,注射的总剂量中,56.3%至62%的HI-6以原形经尿液排出。研究期间,受试者未报告任何副作用,临床或实验室检查也未发现异常。本研究发现人类对HI-6具有极高的耐受性,同时其在沙林、VX和梭曼实验性中毒中的高效性也得到证实,这使其成为治疗已知化学战神经毒剂所致人体中毒最具前景的肟类药物。